Company / Current Liabilities
Viridian Therapeutics, Inc.\DE Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$70.7M
FY2025
5-year range
$13.6M / $70.7M
FY2021-FY2025
Trend
+47.7%
vs FY2024
Sector context
#120 of 213
Health Care
What the data says
At $71M, Viridian Therapeutics, Inc.\DE's current liabilities ranks #94 of 213 in the Health Care sector. Current Liabilities has fluctuated over the past 10 years, ranging from $4M in FY2017 to $71M in FY2025.
Based on SEC 10-K filings.
$71M in FY2025 with a 5-year CAGR of +46.0%.
Increased from $27M to $71M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +28.5%
- 5-Year CAGR
- +46.0%
- 10-Year CAGR
- -
Sector benchmark
#94 of 213 in Health CareTop 44% of 213This company $70.7M Sector average $1.6B
▼
-95.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +46.0%, indicating consistent growth.
- In FY2025, current liabilities increased 47.7% year-over-year.
- Ranks #120 out of 213 companies in the Health Care sector.
- Lowest current liabilities in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $70.7M | +47.7% |
| FY2024 | $47.9M | +79.7% |
| FY2023 | $26.6M | -20.1% |
| FY2022 | $33.3M | +144.6% |
| FY2021 | $13.6M | +27.7% |
| FY2020 | $10.7M | +4.9% |
| FY2019 | $10.2M | +51.2% |
| FY2018 | $6.7M | +72.8% |
| FY2017 | $3.9M | -43.4% |
| FY2016 | $6.9M | +179.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026